Kantoff PW - Search Results

1

Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.

Chan JM, Darke AK, Penney KL, Tangen CM, Goodman PJ, Lee GM, Sun T, Peisch S, Tinianow AM, Rae JM, Klein EA, Thompson IM Jr, Kantoff PW, Mucci LA. Chan JM, et al. Among authors: kantoff pw. Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1050-1058. doi: 10.1158/1055-9965.EPI-16-0104. Epub 2016 May 6. Cancer Epidemiol Biomarkers Prev. 2016. PMID: 27197287 Free PMC article. Clinical Trial.

2

Detection of circulating tumor cells in men with localized prostate cancer.

Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W, et al. Seiden MV, et al. Among authors: kantoff pw. J Clin Oncol. 1994 Dec;12(12):2634-9. doi: 10.1200/JCO.1994.12.12.2634. J Clin Oncol. 1994. PMID: 7527455

3

A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis.

Kantoff PW, Febbo PG, Giovannucci E, Krithivas K, Dahl DM, Chang G, Hennekens CH, Brown M, Stampfer MJ. Kantoff PW, et al. Cancer Epidemiol Biomarkers Prev. 1997 Mar;6(3):189-92. Cancer Epidemiol Biomarkers Prev. 1997. PMID: 9138662

4

The androgen receptor gene GGN microsatellite and prostate cancer risk.

Platz EA, Giovannucci E, Dahl DM, Krithivas K, Hennekens CH, Brown M, Stampfer MJ, Kantoff PW. Platz EA, et al. Among authors: kantoff pw. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):379-84. Cancer Epidemiol Biomarkers Prev. 1998. PMID: 9610786 Clinical Trial.

5

Debrisoquine hydroxylase (CYP2D6) and prostate cancer.

Febbo PG, Kantoff PW, Giovannucci E, Brown M, Chang G, Hennekens CH, Stampfer M. Febbo PG, et al. Among authors: kantoff pw. Cancer Epidemiol Biomarkers Prev. 1998 Dec;7(12):1075-8. Cancer Epidemiol Biomarkers Prev. 1998. PMID: 9865424

6

Prognostic indicators in hormone refractory prostate cancer.

George DJ, Kantoff PW. George DJ, et al. Among authors: kantoff pw. Urol Clin North Am. 1999 May;26(2):303-10, viii. doi: 10.1016/s0094-0143(05)70070-7. Urol Clin North Am. 1999. PMID: 10361553 Review.

7

The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer.

Febbo PG, Kantoff PW, Platz EA, Casey D, Batter S, Giovannucci E, Hennekens CH, Stampfer MJ. Febbo PG, et al. Among authors: kantoff pw. Cancer Res. 1999 Dec 1;59(23):5878-81. Cancer Res. 1999. PMID: 10606227 Clinical Trial.

8

No association between the I105V polymorphism of the glutathione S-transferase P1 gene (GSTP1) and prostate cancer risk: a prospective study.

Shepard TF, Platz EA, Kantoff PW, Nelson WG, Isaacs WB, Freije D, Febbo PG, Stampfer MJ, Giovannucci E. Shepard TF, et al. Among authors: kantoff pw. Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1267-8. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 11097238 No abstract available.

9

PTEN polymorphism (IVS4) is not associated with risk of prostate cancer.

George DJ, Shepard TF, Ma J, Giovannucci E, Kantoff PW, Stampfer MJ. George DJ, et al. Among authors: kantoff pw. Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):411-2. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11319185 No abstract available.

10

The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.

Haiman CA, Stampfer MJ, Giovannucci E, Ma J, Decalo NE, Kantoff PW, Hunter DJ. Haiman CA, et al. Among authors: kantoff pw. Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):743-8. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11440959

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

482 results

Search Page

Filters